- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00135161
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
December 6, 2022 updated by: University Hospital, Ghent
The purpose of this trial is to study fluorodeoxyglucose-positron emission tomography (FDG-PET)-based dose escalation using intensity modulated radiation therapy (IMRT).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The dose escalation, based on the FDG-PET signal, is incorporated in the first ten fractions of the radiotherapeutic treatment.
The total amount of fractions is 32, equal to a standard radiotherapeutic treatment for these types of cancers.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ghent, Belgium, 9000
- University Hospital Ghent
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a proven histological squamous cell carcinoma of the larynx (only T3-4 NO or Tany N+), hypopharynx, oropharynx
- Patients who did not undergo surgery for the primary tumor location
- Patients with a Karnofsky performance score of 70% or more
- Written informed consent for participation in this trial
Exclusion Criteria:
- Other malignancy except for non-melanoma skin cancer
- Prior irradiation to the head and neck region
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensity modulated radiation therapy (IMRT).
|
FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Acute toxicity during radiotherapy until 3 months after the end of the radiotherapy
Time Frame: until 3 months after the end of the radiotherapy
|
until 3 months after the end of the radiotherapy
|
Observation of chronic toxicity
Time Frame: until 3 months after the end of the radiotherapy
|
until 3 months after the end of the radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Therapy response (2-4 months after end of radiotherapy)
Time Frame: 2-4 months after end of radiotherapy
|
2-4 months after end of radiotherapy
|
Local control at 2 years
Time Frame: at 2 years
|
at 2 years
|
Pattern of recurrence
Time Frame: at 2 years
|
at 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2003
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
August 24, 2005
First Submitted That Met QC Criteria
August 24, 2005
First Posted (Estimate)
August 25, 2005
Study Record Updates
Last Update Posted (Estimate)
December 8, 2022
Last Update Submitted That Met QC Criteria
December 6, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2003/202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Washington University School of MedicineRecruitingEndometrial CancerUnited States
-
St. Jude Children's Research HospitalMayo ClinicTerminatedAbdominal NeuroblastomaUnited States
-
Washington University School of MedicineActive, not recruiting
-
NYU Langone HealthCompleted
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Cognitive/Functional EffectsUnited States, Canada
-
M.D. Anderson Cancer CenterCompletedLung Cancer | MesotheliomaUnited States
-
Stanford UniversityVarian Medical SystemsCompletedHead and Neck CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingSquamous Cell Carcinoma of Head and NeckUnited States